YOU'RE LUCKY!

We're fundraising!

OUR COMPANY PROFILE

FOUNDERS & EXPERTISE

Sabrina Fiorentino

Co-Founder & CEO | Pharmacist

Silvia Fiorentino

Co-Founder | Biologist & Nutritionist

Sonia Elicio

CMO | Growth Strategist Manager

Gloria Elicio

COO | Omnichannel Content Creator

Description

Sestre is a Femtech startup, that supports fertility and female hormonal balance thanks to a 360° approach. First of all, we study and market nutraceutical products based on extracts from the Mediterranean Diet, identifying epigenetic compounds to restore physiological pathways; then we follow our patients’ treatment through a digital platform which supports women in monitoring progress and giving them specialist assistance thanks to the Sestre scientific community.

Need Addressed

Sestre operated in the nutraceutical integration field, addressing its offer to women between 20-45 years old who are looking for pregnancy and are suffering from chronic diseases that compromise their fertility and life quality.

Product & Technological Innovation

Sestre offers a complete nutraceutical treatment to replace drug-based hormone therapy. Our nutraceutical products must follow our formulation approach which comprehends: 
1. Choosing KM zero raw materials at least for 80% of ingredients;
2. Studying the synergies among Mediterranean Diet based nutrients to find epigenetics compounds;
3. Dosing each ingredient according to a homoeopathic approach;
4. Conducting studies based on in-vitro tests.

Sestre fertility treatment is also supported by a proprietary web platform which collects and analyses data from patients in order to provide customized aid in achieving their health goals.  On the company hand, Sestre exploits these data collections to improve production and finds continuously new needs,  reducing the risk of launching new products.

Market & Competition

Fertility Supplements Market is worth around € 1.8bn and is growing strongly.

Compare to competitors, Sestre supplements are 100% Science Based. Our formulation are created from scientific papers and tested in vitrus with the University of Bari. Moreover, our Raw Material comes from KM0 Cultivation.

Business Model

Supplements sales through the following channels:

B2C

proprietary e-commerce, Amazon and selected
channels;

B2B2C:

pharmaceutical distributors pharmacies; content
strategy.

Sestre's Launch Year

Sestre was founded in 2019.

Previous fundings

2022: 150k from Public Financing “Tecnonidi”

Financials & Traction

BDG 2022: 120k

CAC: 24€

LTVC: 106€

Customers online: +1000

Distributors: +8

Direct Pharmacies: +40

Prescribers: +50

Cash Need

Round 2023-2024: 1M€

Round by the end of 2023: 500k€

This round will be divided in this way:

18% Platform Dev

20% Marketing

22% HR

40% Sales

Thank you for your interest in our company!

Ehy, keep in touch!

PIVA 08093930728

+39 0883 63 10 49 amministrazione@sestre.it

Via Oberdan, 9 76015 Trinitapoli (BT) Italy

About